OCULAR THERAPEUTIX, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
OCULAR THERAPEUTIX, INC (OCUL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $5.97 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-05
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $5.97, a 6.80% increase from fiscal 2024.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $5.59, a 104.01% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $2.74, a 44.65% decline from fiscal 2022.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $4.95, a 60.34% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2025-12-31 | $5.97 10-K · filed 2026-02-05 |
| 2024-12-31 | $5.59 10-K · filed 2026-02-05 |
| 2023-12-31 | $2.74 10-K · filed 2026-02-05 |
| 2022-12-31 | $4.95 10-K · filed 2025-03-03 |
| 2021-12-31 | $12.48 10-K · filed 2024-03-11 |
| 2020-12-31 | $5.93 10-K · filed 2023-03-06 |
| 2019-12-31 | $2.99 10-K · filed 2021-03-11 |
| 2018-12-31 | $4.48 10-K · filed 2020-03-12 |
| 2017-12-31 | $6.44 10-K · filed 2020-03-12 |
| 2016-12-31 | $4.52 10-K · filed 2019-03-07 |
| 2015-12-31 | $18.12 10-K · filed 2018-03-08 |
| 2014-12-31 | $6.55 10-K · filed 2017-03-10 |
| 2013-12-31 | $1.51 10-K · filed 2016-03-10 |
| 2012-12-31 | $0.87 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |